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with prescribed drug therapy, such as antimuscarinic agents. We
evaluated cost-effectiveness outcomes associated with toltero-
dine extended release (TER), oxybutynin immediate release
(OIR), and no active drug treatment in Germany and the UK
(UK). METHODS: A decision-analytic model was developed for
the analysis. The primary endpoint was cost-effectiveness per
patient achieving persistent control (continuing therapy 6
months after initial prescription). A large case-controlled study
(N = 10,041 per arm) was used to estimate persistence. Resource
uses included in the model were the cost of drugs, regular physi-
cian visits, incontinence pads, and the cost of urinary tract and
skin infections. These were for controlled and uncontrolled
OAB. Costs were estimated from the perspective of the health
care systems of Germany and the UK. Sensitivity analyses
included variation of the time horizon of the analysis, unit costs,
and outcomes achieved. Cost-effectiveness ﬁgures were con-
verted to EUR2004 at market rates. RESULTS: The expected
number of patients achieving persistent control at 6 months was
44% with TER and 20% with OIR. The expected cost-effec-
tiveness per patient during 6 months in Germany was 420.89€
with TER, 224.54€ with OIR, and 51.13€ with no treatment; in
the UK, respective costs were 439.20€, 292.60€, and 23.30€. The
incremental cost-effectiveness per patient achieving persistent
control for TER compared with no treatment was 951.70€ in the
UK and 846.13€ in Germany, and compared with OIR, it was
608.28€ in the UK and 814.71€ in Germany. The model was
most sensitive to changes in the time horizon considered and
dose of drugs required. CONCLUSION: More than twice as
many patients achieved persistent control with TER than with
OIR. This persistence resulted in superior cost-effectiveness for
TER compared to OIR in both the UK and Germany.
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OBJECTIVES: Overactive bladder (OAB) is a common, chronic
and distressing medical condition that affects individuals of all
ages, and is associated with an increased risk of comorbidities.
Tolterodine is an antimuscarinic drug indicated for the treatment
of OAB, and is available as both an immediate-release (IR),
twice-daily, tablet formulation of tolterodine and extended-
release (ER), once-daily, capsule formulation. The aim of this
analysis is to carry out an economic evaluation of IR versus ER
tolterodine in the management of OAB in Spain. METHODS: A
cost-effectiveness analysis was performed by building a decision
analytic model. Efﬁcacy, tolerability and healthcare resource uti-
lization data were obtained from a double-blind, multicenter,
randomized trial showing that ER formulation was more effec-
tive and better tolerated than the IR formulation 1. Only direct
medical costs-drug acquisition, physician visits, diagnostic eval-
uations, incontinence pads and treatment of skin complications
and urinary tract infection-were taken into account. Drug costs
were obtained from ofﬁcial sources, and the rest of data were
taken from a national health care cost database. The perspective
selected for this analysis was primary care assistance and the time
horizon was 12 weeks, the treatment period in the referenced
clinical trial. RESULTS: The percentage of patients treated with
ER tolterodine had a greater control on OAB symptoms (71%
vs 60%, p < 0.05) and a lower cost/effectiveness ratio (375 vs
414€ per patient with successful outcome) than patients treated
with IR tolterodine. CONCLUSIONS: This model demonstrates
that ER tolterodine is a more efﬁcient therapeutic option than
IR tolterodine despite of the difference in acquisition costs
between the two formulations. Therefore, ER could be consid-
ered as the tolterodine formulation to be selected routinely in the
management of OAB in Spain. Van Kerrebroeck et al. Urology
57: 414–421, 2001.
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OBJECTIVE: Urinary tract infections (UTIs) often lead to recur-
rent episodes of UTI, which are generally treated with antibiotics
but the latter may induce bacterial resistance. URO-VAXOM®
in addition to antibiotics reduces the incidence and severity of
UTIs and improves treatment success. The objective of this deci-
sion analysis is to assess the economic impact of URO-
VAXOM® taken in addition to standard medication.
METHODS: A Markov model was developed for the analysis.
As the health outcome variables both symptom-free quarters and
disutilities due to UTIs were chosen. The model simulates the
course of recurrent UTI-patients over 4 consecutive quarters. A
recent randomised, multinational double-blind clinical trial con-
ducted in 52 centres was used to calculate the treatment effect
and the quarterly transition rates. Resource use included were
the cost for drugs, general practitioner and specialist visit costs.
Costs were estimated from the societal perspective within the
framework of the German health care system. Indirect costs for
absence from work were based on days off work reported in the
clinical trial. Sensitivity analyses included variation of the unit
costs and outcomes achieved. RESULTS: The Markov analysis
resulted in 2.82 total symptom-free quarters for the placebo
treatment group and 3.33 for the URO-VAXOM® treatment
group. The cumulated effect over 4 quarters for the quality-
adjusted life-years was 0.995 for the placebo treatment group
and 0.999 for the URO-VAXOM® treatment group. The incre-
mental cost effectiveness ratio (ICER) was 182€ for each addi-
tional symptom-free quarter generated and 23,500€ for each
additional quality-adjusted life-year in Germany. The ICER was
robust to variation of assumptions. CONCLUSION: Despite the
decline of antibiotic’s costs this economic analysis of the ran-
domised, double-blind clinical trial showed that adding URO-
VAXOM® to the standard treatment regimen has a favourable
cost-beneﬁt ratio, far below values internationally considered to
be cost-effective.
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OBJECTIVES: Overactive bladder (OAB) is a costly chronic
health condition affecting women and men of all ages. This study
assessed the relationship between patient perception of OAB
drug therapy success, and associated resource use. METHODS:
A descriptive, cross-sectional survey was conducted via the inter-
net in January 2004 in individuals diagnosed with and using
various therapies for OAB identiﬁed in the 2003 National Health
and Wellness Survey. Health care resource use in the previous 6
months was compared between those who considered themselves
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successfully treated and not successfully treated with prescrip-
tion medication alone. Resource use included type and number
of physician visits, diagnostic tests, and type and number of OAB
complications, as well as monthly out-of-pocket expenses asso-
ciated with OAB, such as over the counter medications, co-pay-
ments for prescription medications, incontinence pads, and
laundry and dry cleaning. Statistical signiﬁcance was evaluated
at the a = 0.05 level. RESULTS: In total, 196 adults receiving
drug therapy for their OAB (mean age 63.4 years, 76% female)
responded to the survey, of whom 121 (62%) perceived them-
selves to be successfully treated. In general, respondents who
considered their OAB condition successfully treated tended to
consume signiﬁcantly fewer resources than respondents who
considered their OAB unsuccessfully treated, including: visits to
a primary care physician (0.9 vs 1.4, p < 0.01); urine tests (0.2
vs 0.5, p = 0.05); and pads used during the day (0.9 vs 1.9, p <
0.01); and experienced fewer urinary tract infections (0.3 vs 0.9,
p < 0.02). Median monthly out-of-pocket expenses for OAB
were $18 for successfully treated versus $30 for unsuccessfully
treated respondents (p < 0.05). CONCLUSIONS: Patients who
consider themselves successfully treated with OAB medications
consume fewer resources and incur fewer out-of-pocket
expenses. OAB drug therapies that increase patient perception of
treatment success could potentially lead to lower healthcare
resource consumption.
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OBJECTIVE: Reducing protein intake of patients with chronic
renal disease (CRD) signiﬁcantly reduces the number of patients
entering end-stage renal disease (ESRD). We conducted an eco-
nomic evaluation of dietary protein restriction on the progres-
sion of CRD. METHODS: We conducted a Cost-Beneﬁt Analysis
in the perspective of the Italian National Health Service (NHS)
based on data from Modiﬁcation in Diet in Renal Disease
(MDRD) Study. In the MDRD, patients with a glomerular ﬁl-
tration rates (GFR) of 25–55ml/min/1.73m2 were randomly
assigned to usual protein (1.3g/Kg/die) or low protein 
(0.58g/Kg/die) diet groups. It is expected that a patient would
receive a protein-restricted diet when his/her GFR falls under 
25ml/min/1.73m2 and to start dialysis when his/her GFR is 
5ml/min/1.73m2. We quantiﬁed cost of diet with aprotein
product (2000Kcal/die, 40gr/die of protein) and the assistance
of a nutritionist (once every two months) and cost of dialysis
using NHS tariffs. Data were applied to a 7 years time horizon.
We conducted a one-way sensitivity analysis varying costs and
beneﬁts by ± 10% and applied a 3% rate of discount. RESULTS:
Applying the mean decline of GFR obtained by the MDRD study
we estimated patients receiving a low protein intake to start dial-
ysis in 7 years. Patients with a usual protein diet would start dial-
ysis in 5 years. We estimated a cost of 6882€ for 7 years low
protein diet with aprotein products. This treatment would delay
by 2 years dialysis initiation with an estimated saving to the NHS
of 43,268€. We obtained a beneﬁt of 36,386€ per patient. These
results were robust in one-way sensitivity analyses. CONCLU-
SION: Using MDRD Study data, a low protein controlled diet,
in nephropatic patients, could delay the degeneration of
nephropathy extending the renal survival. This involves signi-
ﬁcative economic beneﬁts.
PUK6
COST OF RENAL TRANSPLANTATION IN BELGIUM
Lecomte P1, Chaib Eddour D2, Squifﬂet JP2
1Novartis Pharma,Vilvoorde, Brussels, Belgium; 2Cliniques UCL 
Saint-Luc, Brussels, Belgium
OBJECTIVE: The objective of this project was to analyse the 1-
year direct medical costs of kidney transplantation performed in
Belgium. METHODS: Data from the last 150 patients who
received a kidney transplantation at UCL Cliniques Universi-
taires St Luc (Belgium) and for which a follow-up of 1-year was
available were analysed. All patients were adults at the age of
the transplantation and treated with cyclosporine. Patients ﬁles
were retrospectively analysed. Key parameters, such as: primary
hospitalisation for transplantation; immunosuppressive drug
use; patient survival; graft survival; acute rejection; CMV infec-
tion; other adverse events and serious complications; treatment
of adverse events; treatment of complications; repeat hospital-
ization; and follow-up hospital consultations were recorded.
Total length of stay in the hospital was also recorded. For each
patient, information up to 1-year post renal transplantation (or
until death if death occurred within 1-year of transplantation)
was collected. Costing information was obtained from anony-
mous hospital bills which provided amounts paid by the health
care payer and patient. Three perspectives were considered in
this study, i.e. the health care payer (INAMI/RIZIV), the patient,
and the societal perspectives. RESULTS: For the whole popula-
tion (n = 150), the mean direct medical costs from the societal
perspective, health care payer’s perspective, and patient’s per-
spective amounted to 40,574€, 38,566€ (of which 28,844€ for
hospitalisation only), and 2,008€, respectively. During this one
year period, patients were hospitalised for 29 days on average.
CONCLUSIONS: One year direct medical costs of kidney trans-
plantation are substantial. In Belgium, most of the direct medical
costs are borne by the health care payer, and the main cost driver
are hospital costs.
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OBJECTIVE: This analysis characterizes patients in need of high
EPO doses at still low Hb levels of below 10g/dl (poor EPO
response). Cost-effectiveness of TR in such cohort is assessed.
METHODS: A database (>9000pat.) was stratiﬁed by EPO
dosage and Hb level and analyzed according to several medical
outcome parameters. A cohort of pat with poor EPO response
was compared to patients with an EPO dosis of 2,500–10,600
(mean ± 1 SD) and a mean Hb level of 11.5g/dl. Costs and con-
sequences of EPO therapy and TR were analyzed for the cohort
of pat with poor EPO response. RESULTS: Patients (n = 233)
with poor EPO response (18,730U/week) showed a mean Hb
level of 9.0g/dl and a higher prevalence of cerebrovascular, liver,
and valvular heart disease and fewer days of hospital free sur-
vival time of 223 days compared to 273 days in the compara-
tive arm. The yearly costs of EPO therapy (15,660€) outweigh
the costs of transfusion therapy (5,250€) assuming 50 blood
units per year. CONCLUSION: Given the relatively sick popu-
lation with poor EPO response, the risks associated with TR such
as infections and iron overload is outbalanced. Since mortality
(historical group) and QoL (SF-36) data are available for these
groups, the cost-effectiveness (cost per QALY) will be calculated.
